Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
暂无分享,去创建一个
P. Rossing | F. Persson | P. Banks | D. Vistisen | M. Davies | E. Stougaard | Manon Girard | Phillip L. Banks